Predicting cardiovascular disease in familial hypercholesterolemia

Area of Science:

• Cardiovascular Medicine
• Genetics
• Pharmacology

Background:

• Familial hypercholesterolemia (FH) is a common genetic disorder significantly elevating lifetime cardiovascular disease (CVD) risk.
• Statins are primary FH treatments, but emerging therapies necessitate improved identification of patients with residual CVD risk.
• Accurate risk stratification is crucial for optimizing treatment in FH.

Purpose of the Study:

• To review recent advancements in cardiovascular risk stratification for familial hypercholesterolemia.
• To highlight novel clinical and genetic predictors of CVD in FH patients.

Main Methods:

• Review of recent literature on cardiovascular risk stratification in familial hypercholesterolemia.
• Identification and analysis of clinical scores (e.g., Montreal-FH-SCORE), protein biomarkers, carotid plaque scores, and genetic predictors (genetic risk scores, SNPs).

Main Results:

• Several clinical and genetic factors have emerged as independent predictors of CVD in FH.
• These include established scores, novel biomarkers, imaging data, and genetic risk assessments.
• Current predictors do not fully account for the total cardiovascular risk in FH.

Conclusions:

• Progress has been made in FH cardiovascular risk stratification.
• Further research is needed to understand phenotype modifiers and refine individual risk prediction.
• Enhanced risk stratification will enable more tailored and effective therapies for FH patients.